Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR) is a fixed-dose combination antihyperglycemic formulation. It integrates the dual advantages of sitagliptin (a dipeptidyl peptidase-4 inhibitor) and extended-release metformin, and is indicated for adult patients with type 2 diabetes whose blood glucose is inadequately controlled by diet and exercise alone.

Precautions for Administration of Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Baseline Assessment of Renal Function

Before initiating Sitagliptin/Metformin Hydrochloride Extended-Release Tablets, renal function must be assessed by estimating the glomerular filtration rate (eGFR).

Use is contraindicated in patients with an eGFR of less than 30 mL/min/1.73 m².

Initiation of treatment is not recommended for patients with an eGFR between 30-45 mL/min/1.73 m².

For patients already on treatment, if the eGFR subsequently drops below 45 mL/min/1.73 m², the benefits and risks of continued treatment must be re-evaluated, and the dose of sitagliptin should be limited to 50 mg per day.

Contraindication Screening

Severe renal impairment (eGFR < 30 mL/min/1.73 m²).

Metabolic acidosis or diabetic ketoacidosis.

A history of severe hypersensitivity to sitagliptin, metformin, or any component of the fixed-dose combination formulation.

Screening for Special Populations

Elderly patients aged ≥ 65 years require more frequent monitoring of renal function.

Use should be avoided in patients with hepatic impairment.

Specialized assessment is necessary for women who are pregnant or breastfeeding.

Medication Monitoring for Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Dynamic Monitoring of Renal Function

All patients should undergo eGFR testing at least once a year.

The frequency of monitoring should be increased for populations at high risk of renal function decline (e.g., elderly patients).

Early Warning for Lactic Acidosis

Be alert to non-specific symptoms such as malaise, myalgia, dyspnea, drowsiness, or abdominal pain.

Laboratory abnormalities include elevated blood lactate levels, anion gap acidosis, and a plasma metformin concentration typically > 5 mcg/mL.

Monitoring of Key Adverse Reactions

Pancreatitis Identification: Closely monitor for symptoms such as abdominal pain radiating to the back. If pancreatitis is suspected, discontinue the medication immediately and initiate targeted treatment.

Cardiac Function Monitoring: For patients with known risk factors for heart failure, monitor for symptoms such as rapid weight gain and dyspnea.

Screening for Vitamin B12 Deficiency: Conduct hematological parameter testing annually and measure vitamin B12 levels every 2-3 years.

Hypoglycemia Risk Management: When used in combination with insulin or insulin secretagogues, the dose of insulin or secretagogues should be reduced.